Oak Hill Bio Investor Deck Reveals Rugonersen Phase 3 Trial Design and New Efficacy Data
RACC is trading near its 52-week low of $10.21 (9.9% above the low) on light trading volume (0.1× avg).
Summary
Oak Hill Bio's September 2026 investor presentation discloses new Phase 3 trial details and preclinical efficacy data for rugonersen, its lead Angelman syndrome drug, ahead of the planned SPAC merger with Research Alliance Corp III.
Key Events · M&A and Partnerships · RACC
-
BEACON Phase 3 Trial Underway
First patient dosed July 2026; sham-controlled, 1:1 randomized, N=165 (ages 1-50), primary analysis N=135 (ages 1-17). Primary endpoint: BSID-4 Raw Cognition or Expressive Communication. Topline data expected early 2029.
-
Rugonersen Dosing Regimen
Phase 3 dose is 120mg every 12 weeks (Q12W), with a 56-week double-blind period followed by an open-label extension.
-
Head-to-Head Potency Claims
Preclinical data shows rugonersen 20-100 fold more potent at inducing UBE3A protein than GTX-102 (Ultragenyx) and ION582 (Ionis), with ~100% protein expression increase in primates vs 41% for GTX-102.
-
TANGELO Phase 1 LTE Results
Long-term extension data shows improvement above natural history expectation in 10 out of 10 BSID-III and VABS-III domains, with strongest effects on cognition and expressive communication.
Analysis · RACC · Life Sciences
This investor presentation adds substantial new clinical detail to the previously announced SPAC merger. The BEACON Phase 3 trial for rugonersen in Angelman syndrome has already dosed its first patient (July 2026), with topline data expected in early 2029. The deck also presents head-to-head preclinical data claiming rugonersen is 20-100 fold more potent than competing ASOs from Ultragenyx and Ionis, and TANGELO Phase 1 long-term extension results showing improvement in 10 out of 10 clinical domains. For a company whose entire value rests on a single drug candidate, these data points materially sharpen the investment thesis — both the upside (differentiated efficacy) and the timeline risk (no pivotal data for nearly three years).
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RACC was trading at $11.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.1M. The 52-week trading range was $10.21 to $33.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.